Department of Chest Disease, Dicle University, Diyarbakir, Turkey.
Eur Rev Med Pharmacol Sci. 2013 May;17(9):1233-41.
Malignant pleural mesothelioma (MPM) is a fatal malignancy. Radiological imaging is necessary for the diagnosis, staging, and clinical management of patients with MPM. The 18 fluorodeoxyglucose positron emission tomography (18 FDG-PET) scan has proven useful in preoperative staging and as a prognostic tool in MPM. We aimed to investigate the relationship between the pre-treatment 18 FDG PET/CT results, together with other known clinical parameters, and the survival of patients with MPM in our region.
A retrospective analysis was performed on the data of 177 patients with MPM between April 2007 and April 2011. Pre-treatment 18 FDG PET/CT scans were done on all patients. Survival time was calculated by the Kaplan-Meier method.
The mean age was 55.40 years. There were 56% male patients and 44% female patients. The mean survival time was 11 months from time of diagnosis. According to multivariate analysis results, being of male gender increased the poor prognosis 5.30 times, a Karnofsky performance score (KPS) < 60 increased a poor prognosis 2.18 times, being on "best supportive care" increased a poor prognosis 25.40 times, the stage III-IV increased a poor prognosis 11.13 times, and a level of maximum standardized uptake value (SUVmax) > 5 increased a poor prognosis 4.34 times.
MPM remains a fatal prognosis. Significant predictors of survival include KPS, stage of disease, gender, treatment regimen and level of SUVmax. An understanding of the importance of these markers for MPM prognosis should allow targeted treatments to be developed.
恶性胸膜间皮瘤（MPM）是一种致命的恶性肿瘤。影像学检查对于 MPM 患者的诊断、分期和临床管理是必要的。18 氟脱氧葡萄糖正电子发射断层扫描（18 FDG-PET）在术前分期和 MPM 的预后评估中已被证明是有用的。我们旨在研究我们地区 MPM 患者治疗前 18 FDG PET/CT 结果与其他已知临床参数之间的关系，以及与患者的生存情况的关系。
对 2007 年 4 月至 2011 年 4 月期间的 177 例 MPM 患者的数据进行回顾性分析。所有患者均行治疗前 18 FDG PET/CT 扫描。通过 Kaplan-Meier 法计算生存时间。
平均年龄为 55.40 岁。男性患者占 56%，女性患者占 44%。从诊断时起，平均生存时间为 11 个月。根据多变量分析结果，男性性别使预后不良的风险增加 5.30 倍，Karnofsky 表现评分（KPS）<60 使预后不良的风险增加 2.18 倍，接受“最佳支持治疗”使预后不良的风险增加 25.40 倍，III-IV 期使预后不良的风险增加 11.13 倍，最大标准化摄取值（SUVmax）>5 使预后不良的风险增加 4.34 倍。
MPM 仍然是一种预后不良的疾病。生存的显著预测因素包括 KPS、疾病分期、性别、治疗方案和 SUVmax 水平。了解这些标志物对 MPM 预后的重要性，应能促使开发针对这些标志物的靶向治疗方法。
